Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of Accounting for Stock-Based Compensation

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:


	Nine Months Ended
	September 30,
	2020		2019

Employee and director stock option grants:
Research and development	$	50,071	$	47,825
General and administrative		303,010		611,074
Total stock-based compensation	$	353,081	$	658,899

Schedule of Stock Options Activity

A summary of stock option activity is as follows:


				Weighted
	Number of			Average
	Shares Issuable			Remaining
	Upon Exercise	Weighted		Contracted	Aggregate
	of Outstanding	Average		Term in	Intrinsic
	Options	Exercise Price		Years	Value
Outstanding at December 31, 2019	610,714	$	6.78	8.83	$	34,750
Granted	653,750	$	1.84
Forfeited	(80,000)	$	2.46
Outstanding at September 30, 2020	1,184,464	$	4.34	8.82	$	—

Exercisable, September 30, 2020	432,096	$	8.62	7.94	$	—
Unvested, September 30, 2020	752,368	$	1.88	9.33	$	—

Schedule of Restricted Stock Grants

The following table summarizes the restricted stock grants:


		Weighted
		Average
		Grant Date		Total Grant
	Number of	Fair Value		Date Fair
	Shares	Per Share		Value
Outstanding at December 31, 2019	9,334	$	21.00	$	196,000
Vested	(9,334)	$	21.00	$	(196,000)
Outstanding at September 30, 2020	—	$	—	$	—